By David Sachs


Merck's multiple sclerosis drug evobrutinib didn't meet a key goal in late-stage trials.

The German pharmaceutical company's phase 3 clinical trials for the drug did not achieve their primary target of reducing annualized relapse rates in people with relapsing multiple sclerosis, it said late Tuesday. The drugmaker was aiming to match the rate of Aubagio, an oral drug for the disease owned by Sanofi.

"While we are very disappointed with the results, we continue to advance our strategy in healthcare with a focus on progressing our marketed portfolio and internal pipeline, complemented by external innovation, with the aim of bringing more medicines to patients, faster," said Danny Bar-Zohar, head of research and development at Merck.


Write to David Sachs at david.sachs@wsj.com


(END) Dow Jones Newswires

12-06-23 0122ET